A Wall-Street Journal analysis looks at the AIDS-drug market, and finds that "pharmaceutical giants seek to blunt a growing threat from generic-drug companies and recoup some moral high ground amid the crippling epidemic." The story reports on the slashing of the prices by the biggest drug-makers. It also includes a table of prices for AIDS per patient per year in the U.S. and Africa offered by large drug makers and two Indian generic drug companies.
This file is not available for digital download. IRE members may place an order by emailing email@example.com